Target Health Inc. has announced the release of Target Document® version 1.5. Target Document® is a distributable, secure, user-friendly, 21 CFR Part 11 compliant, Internet-based, document sharing, distribution, and management system that allows users, depending on their roles and permissions, to post, share, electronically sign, and archive an electronic document within a Web browser. New features include advanced user management, access to recycle bin, parallel sign off of documents, manual backup of any folder, configuration of e-Signature text, document expiration dating, email alerts to all users, etc.
According to Jules Mitchel, MBA, Ph.D., President of Target Health, “Target Document® allows for a paperless Trial Master File (TMF) and is part of the paperless eClinical toolbox of products available from Target Health.”
The Target Health toolbox includes: Target e*CRF®, Target Health’s flagship EDC software, which has been used in clinical trials; Target Encoder® - which links into the Target e*CRF® database to encode MedDRA and WHODRUG terms; Target e*CTMS™ (Clinical Trial Management System)- which allows for Internet-based project management, across studies at one website ; and Target Newsletter® - which allows for a clinical trial newsletter with real time enrollment data and comments.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.